These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16313894)

  • 1. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.
    Chang HR; Yang SF; Li ML; Lin CC; Hsieh YS; Lian JD
    Clin Chim Acta; 2006 Apr; 366(1-2):243-8. PubMed ID: 16313894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease.
    Nagano M; Fukami K; Yamagishi S; Ueda S; Kaida Y; Matsumoto T; Yoshimura J; Hazama T; Takamiya Y; Kusumoto T; Gohara S; Tanaka H; Adachi H; Okuda S
    Am J Nephrol; 2009; 29(2):109-15. PubMed ID: 18701818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease.
    Zakiyanov O; Kalousová M; Kratochvilová M; Kríha V; Zima T; Tesar V
    Clin Lab; 2012; 58(5-6):471-80. PubMed ID: 22783577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients.
    Chang HR; Kuo WH; Hsieh YS; Yang SF; Lin CC; Lee ML; Lian JD; Chu SC
    Transl Res; 2008 Apr; 151(4):217-23. PubMed ID: 18355769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical usefulness of plasma activities of gelatinase (matrix metalloproteinase-2 and 9) in chronic liver disease].
    Kwon OS; Lim DY; Kwon KA; Chung MG; Park DK; Kim SS; Kim YS; Kwon SY; Koo YS; Kim YK; Choi DJ; Kim JH; Hwang YJ; Byun KS; Lee CH
    Taehan Kan Hakhoe Chi; 2003 Sep; 9(3):222-30. PubMed ID: 14515040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease.
    Chung AW; Yang HH; Sigrist MK; Brin G; Chum E; Gourlay WA; Levin A
    Cardiovasc Res; 2009 Dec; 84(3):494-504. PubMed ID: 19617223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-1, IGFBP-3, VEGF and MMP-9 levels and their potential relationship with renal functions in patients with compensatory renal growth.
    Yildiz B; Kural N; Colak O; Ak I; Akcar N
    Clin Physiol Funct Imaging; 2008 Mar; 28(2):107-12. PubMed ID: 18093232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Chang YH; Lin IL; Tsay GJ; Yang SC; Yang TP; Ho KT; Hsu TC; Shiau MY
    Clin Biochem; 2008 Aug; 41(12):955-9. PubMed ID: 18471998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
    Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus.
    Shiau MY; Tsai ST; Tsai KJ; Haung ML; Hsu YT; Chang YH
    Mt Sinai J Med; 2006 Nov; 73(7):1024-8. PubMed ID: 17195891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of gelatinase and tumor necrosis factor-α level in the vitreous and serum of patients with Eales disease: role of inflammation-mediated angiogenesis in the pathogenesis of Eales disease.
    Sen A; Paine SK; Chowdhury IH; Mukherjee A; Choudhury S; Mandal LK; Bhattacharya B
    Retina; 2011; 31(7):1412-20. PubMed ID: 21394064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
    Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
    Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
    Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia.
    Yang SF; Chu SC; Chiang IC; Kuo WF; Chiou HL; Chou FP; Kuo WH; Hsieh YS
    Clin Chim Acta; 2005 Feb; 352(1-2):209-15. PubMed ID: 15653116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
    Yang SF; Hsieh YS; Lin CL; Hsu NY; Chiou HL; Chou FP; Chu SC
    Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations.
    Barbosa F; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):559-64. PubMed ID: 16700817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
    Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
    Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.